Soligenix Inc. buy melinda
Startpreis
30.08.18
/
50%
20,54 €
Kursziel
01.10.18
32,44 €
Rendite (%)
20,39 %
Endpreis
01.10.18
24,74 €
Zusammenfassung
Diese Einschätzung wurde am 01.10.18 mit einem Endkurs von 24,74 € beendet. Aufwärts ging es für die BUY Einschätzung von melinda mit einer Rendite von 20,39 %. melinda hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Soligenix Inc. | - | - | - | - |
iShares Core DAX® | -0,92 % | -1,99 % | 13,40 % | 16,08 % |
iShares Nasdaq 100 | 0,37 % | -0,87 % | 41,54 % | 46,94 % |
iShares Nikkei 225® | 2,22 % | -5,19 % | 20,50 % | 4,64 % |
iShares S&P 500 | -0,03 % | -0,92 % | 30,41 % | 42,42 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Soligenix Inc diskutieren
SecteurRecherche biotechnologique et médicale Agenda 27/09 | 15:00 Assemblée générale
Manufactures biodefense vaccines and oral therapeutic products
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease.
It operates through the BioTherapeutics, and Vaccines/BioDefense segments.
The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma.
The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate.
The company was founded in 1987 and is headquartered Princeton, NJ.
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease.
It operates through the BioTherapeutics, and Vaccines/BioDefense segments.
The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma.
The Vaccines/BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate.
The company was founded in 1987 and is headquartered Princeton, NJ.
Nombre d'employés : 18 personnes.
(Vom Mitglied beendet)